Related references
Note: Only part of the references are listed.Correlates of protection against SARS-CoV-2 in rhesus macaques
Katherine McMahan et al.
NATURE (2021)
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat
David C. Montefiori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
A Bispecific Antibody That Simultaneously Recognizes the V2-and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
Meredith E. Davis-Gardner et al.
MBIO (2020)
Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?
P. J. Klasse et al.
CELL HOST & MICROBE (2020)
Dissecting the antibody-OME: past, present, and future
Carolin Loos et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody
Mangaiarkarasi Asokan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo
Pengfei Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies
Marina Tuyishime et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey et al.
NATURE MEDICINE (2019)
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge
Amarendra Pegu et al.
CELL HOST & MICROBE (2019)
Multiple roles for HIV broadly neutralizing antibodies
Barton F. Haynes et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
The potential of engineered antibodies for HIV-1 therapy and cure
Marloes Grobben et al.
CURRENT OPINION IN VIROLOGY (2019)
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure
Peter D. Kwong et al.
IMMUNITY (2018)
Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice
Xilin Wu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
Kshitij Wagh et al.
PLOS PATHOGENS (2018)
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Pilar Mendoza et al.
NATURE (2018)
Recent progress in broadly neutralizing antibodies to HIV
Devin Sok et al.
NATURE IMMUNOLOGY (2018)
Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160
Seth H. Pincus et al.
JOURNAL OF VIROLOGY (2017)
Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins
Seth H. Pincus et al.
JOURNAL OF VIROLOGY (2017)
Hunting Down the HIV-1 Reservoir: A Starring Role for Antibodies?
Hugo Mouquet
IMMUNITY (2017)
The HIV-1 envelope glycoprotein structure: nailing down a moving target
Andrew B. Ward et al.
IMMUNOLOGICAL REVIEWS (2017)
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Marina Caskey et al.
NATURE MEDICINE (2017)
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Ling Xu et al.
SCIENCE (2017)
Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail
Boris Julg et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
Matthew R. Gardner et al.
CURRENT OPINION IN HIV AND AIDS (2017)
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Joshua A. Horwitz et al.
CELL (2017)
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
Stylianos Bournazos et al.
CELL (2016)
Bispecific Antibodies Against HIV
David C. Montefiori
CELL (2016)
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
Yaoxing Huang et al.
CELL (2016)
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Johannes F. Scheid et al.
NATURE (2016)
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
K. J. Bar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo
Ching-Lan Lu et al.
SCIENCE (2016)
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
James E. Robinson et al.
NATURE COMMUNICATIONS (2016)
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env
Louise Scharf et al.
CELL (2015)
Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization
M. Asokan et al.
JOURNAL OF VIROLOGY (2015)
CATNAP: a tool to compile, analyze and tally neutralizing antibody panels
Hyejin Yoon et al.
NUCLEIC ACIDS RESEARCH (2015)
Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein
Jia Chen et al.
SCIENCE (2015)
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Stylianos Bournazos et al.
CELL (2014)
Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers
Claudia Blattner et al.
IMMUNITY (2014)
Role of Fc-mediated antibody function in protective immunity against HIV-1
George K. Lewis
IMMUNOLOGY (2014)
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
Marcella Sarzotti-Kelsoe et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2014)
Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
Allan deCamp et al.
JOURNAL OF VIROLOGY (2014)
Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains
Weizao Chen et al.
JOURNAL OF VIROLOGY (2014)
Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity
Maxime Veillette et al.
JOURNAL OF VIROLOGY (2014)
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface
Jinghe Huang et al.
NATURE (2014)
Immunologic strategies for HIV-1 remission and eradication
Dan H. Barouch et al.
SCIENCE (2014)
Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
Dan H. Barouch et al.
NATURE (2013)
Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design
Mattia Bonsignori et al.
JOURNAL OF VIROLOGY (2012)
Identification and Characterization of a Broadly Cross-Reactive HIV-1 Human Monoclonal Antibody That Binds to Both gp120 and gp41
Mei-Yun Zhang et al.
PLOS ONE (2012)
Anti-HIV Double Variable Domain Immunoglobulins Binding Both gp41 and gp120 for Targeted Delivery of Immunoconjugates
Ryan B. Craig et al.
PLOS ONE (2012)
Enhanced HIV-1 neutralization by antibody heteroligation
Hugo Mouquet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum
Guido Ferrari et al.
JOURNAL OF VIROLOGY (2011)
Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates
Weizao Chen et al.
ANTIVIRAL RESEARCH (2010)
Evaluation of CD4-CD4i Antibody Architectures Yields Potent, Broadly Cross-Reactive Anti-Human Immunodeficiency Virus Reagents
Anthony P. West et al.
JOURNAL OF VIROLOGY (2010)
Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection
George Sellhorn et al.
VACCINE (2009)
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate
Donald N. Forthal et al.
JOURNAL OF IMMUNOLOGY (2007)
Engineered human IgG antibodies with longer serum half-lives in primates
PR Hinton et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection
SH Pincus et al.
JOURNAL OF IMMUNOLOGY (2003)
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study
WT Shearer et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
JM Jacobson et al.
JOURNAL OF INFECTIOUS DISEASES (2000)